Biocon Share Price Rises Over 6% After Large Block Deal

Biocon share price (NSE: BIOCON ) gained around 6% during intraday trading on Tuesday after a large block deal took place on the National Stock Exchange (NSE). 

During the pre-open session, nearly 45.98 million equity shares, representing about 2.82% of the company's total equity, changed hands through a block deal. The transaction was valued at around ₹1,839.34 crore and was executed at an average price of ₹400 per share.

On the BSE, around 46.54 million shares were traded through block deals. However, the identities of the buyers and sellers were not immediately disclosed.

Following the transaction, Biocon shares touched ₹434 during intraday trade, moving close to their 52-week high. The stock outperformed the broader market, even as the Nifty 50 traded in negative territory.

Biocon's Business Overview

Biocon is a global biopharmaceutical company that develops affordable medicines for patients across the world. Its business includes biosimilars and generic medicines, serving therapeutic areas such as diabetes, cancer, obesity, cardiovascular diseases, immunology, ophthalmology and bone health.

The company has launched 12 biosimilar products and more than 30 generic formulations globally. It also has a strong research pipeline comprising over 20 biosimilar assets, GLP-1 peptides and other complex generic products.

Management's Outlook for FY27

During its Q4 earnings conference call, Biocon said its biosimilars business has entered FY27 from a position of strength, supported by a wider product portfolio, an expanding global presence and improving profitability.

The company stated that the integration phase is now complete, major investments have largely been made, and its balance sheet has strengthened significantly.

Going forward, management plans to focus on disciplined execution, accelerating growth, improving operating margins and delivering better returns on capital.

Biocon expects performance to improve gradually during FY27, with new product launches expected to contribute more meaningfully in the second half of the financial year.

The company also expects recent biosimilar launches across different markets to support revenue growth and improve operating leverage.

In its Generics business, the focus will remain on improving profitability as newer products stabilise and manufacturing utilisation improves.

Meanwhile, Syngene will concentrate on strengthening execution and improving performance by leveraging its investments in Contract Research, Development and Manufacturing Organisation (CRDMO) capabilities.

Read More: Nifty Weekly Expiry Today: Kaynes Technology India Under F&O Ban on July 14, 2026

Conclusion

Biocon's strong market reaction to the block deal and its optimistic FY27 outlook reflect investor confidence in the company's growth strategy and expanding biopharmaceutical business.

Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.